Protalix BioTherapeutics
PLX
101 hedge funds and large institutions have $33.7M invested in Protalix BioTherapeutics in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 16 closing their positions.
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
63% more call options, than puts
Call options by funds: $747K | Put options by funds: $459K
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
1% more funds holding
Funds holding: 100 → 101 (+1)
2.98% less ownership
Funds ownership: 20.93% → 17.95% (-3%)
43% less capital inflows, than outflows
Capital inflows: $7.07M | Capital outflows: $12.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$959K |
| 2 |
BlackRock
New York
|
+$910K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$708K |
| 4 |
STRS Ohio
Columbus,
Ohio
|
+$627K |
| 5 |
Goldman Sachs
New York
|
+$476K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAK Capital One
New York
|
-$7.69M |
| 2 |
Prospera Financial Services
Dallas,
Texas
|
-$908K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$738K |
| 4 |
Morgan Stanley
New York
|
-$530K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$450K |
PLX Hedge Fund Activity: Q2 2026 in Review
101 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2026, worth a combined $33.7M — down 7.9% from $36.6M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PLX positions and 16 closed out — a net gain of 2 holders — while 38 added to existing stakes and 17 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $959K. The largest seller was MAK Capital One, exiting entirely with an estimated $7.69M sold.
- 101 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2026, up from 100 in Q1 2026.
- Funds reported $33.7M of Protalix BioTherapeutics stock for Q2 2026, down 7.9% quarter-over-quarter.
- 18 funds opened new Protalix BioTherapeutics positions in Q2 2026 and 16 closed out, a net change of +2 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2026 was Marshall Wace, an estimated $959K added.
- The largest Protalix BioTherapeutics seller in Q2 2026 was MAK Capital One, an estimated $7.69M sold.
Based on aggregated 13F filings for Q2 2026.